> James Mullen, the CEO of Biogen Idec, is retiring in June after leading the biotech company for the seven years. Also, the company has named Caroline Dorsa, EVP and CFO of Public Service Enterprise Group, to fill a vacancy on the board of directors. Mullen story|
> Mark Bagarazzi, former director of worldwide regulatory affairs for vaccines and biologics at Merck, has joined Inovio Biomedical as chief medical officer.
> Proteonomix has announced that Joel Pensley has resigned as secretary, director and general counsel; Roger Fidler has joined the company as director and general counsel; and Steven Byle, presently a director, has assumed the role of secretary.
> BioVex has announced that Tim Hanke will become VP, commercial operations. Hanke will be responsible for preparing for the commercialization of BioVex's investigational product, OncoVEXGM-CSF.
> GeoVax Labs has tapped Mark Newman as VP of R&D. Newman will be responsible for developing GeoVax's therapeutic HIV vaccine initiative and broadening the company's pipeline.
> CrystalGenomics has appointed of Eric Nelson as the VP of business development.
> Noven Pharmaceuticals has appointed Andrew Panagy as VP, marketing & sales and Natalie Estrella as VP, human resources.
> China's Biostar Pharmaceuticals has announced the voluntary resignations of board members Michael Segal and Xifeng Nie. Two independent directors, Zibing "Zack" Pan and Zhongyang Shang, have been named to the board.
> Canada's YM BioSciences has announced that Rogerio Lilenbaum, Minesh Mehta and Roman Perez-Soler, together with two additional American oncologists, have agreed to constitute a U.S. consultative committee to YM on the ongoing development of nimotuzumab and the other anti-cancer molecules being acquired through the proposed merger of Cytopia.